Tromsø, Norway, 27th January 2022 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 40.5 million (22.1) and an EBITDA of NOK 20.8 million (6.8) for the fourth quarter of 2021. Highlights from Q4 2021 ArcticZymes Technologies (AZT) had Q4 sales of NOK 40.5 million – an increase of 84% (Q4 2020: NOK 22.1 million) Exceeded annual sales target achieving …
ArcticZymes AS is delighted to achieve ISO 13485:2016 recertification. ISO 13485:2016 is an internationally recognized medical device standard that demonstrates excellence in Quality Management System´s (QMS) and best practice in product development, manufacturing, and supply of the products to meet the needs of customers and pertinent regulatory requirements. ArcticZymes AS continuously works to strengthen its QMS to ensure that all …
ArcticZymes technologies launches the following products: ArcticZymes R2DTM Ligase – Patent pending ligase with novel specificity enabling the ligation of DNA to both ends of RNA using a DNA splint. The enzyme is an enabling tool for new technology development and is expected to have broad applicability in Molecular Diagnostics (MDx), Next Generation Sequencing (NGS), and gene/RNA synthesis applications …
ArcticZymes Technologies are participating at the 2021 MEDICA congress in Düsseldorf, Germany from 15-18 November. Please come and visit us at our stand in Hall 3/ J09 for a discussion around how we can support your company